Simulations Plus

John R. Kneisel, CPA, to Replace Momoko Beran, Retiring after More Than 20 Years of Service

Leading Provider of Simulation and Modeling Software for Pharmaceutical Discovery and Development to Present on December 3, 2013

Fiscal Year Pharmaceutical Software and Services Up 6.6%

Toxicity predictions to be used to supplement in vitro data as a service

Cash dividend increased to $0.04 per share

Office of Clinical Pharmacology Interested in Program’s Drug-Drug Interaction Capabilities

Full-Year Revenue Up 6.6%; 6th Consecutive Profitable Year

Software Upgrade Adds Numerous Capabilities and User Convenience Features

Company Uses Proprietary Software Tools to Design New Molecules for COX-2 Inhibitors

Prediction of Ionization Constants Key to Many Other Property Predictions

Board increases cash dividend again to $0.03 per share

Software Upgrades Further Expand Powerful Data Mining and Molecule Design Programs, Extend Technological Lead of Simulations Plus

Third quarter net sales increase 11.7%; net income up 14.3%

Conference Call to be on Thursday, July 11, at 4:15 PM ET

Software Programs Will Help Prioritize Testing for the National Toxicology Program

Preliminary Revenues Increased 11.7% for New Record Third Quarter

Software Upgrade Increases Number of Predictive Models, Adds User Convenience Features

US FDA, UK MHRA, and European EMA Accept Simulation Results in Applications

Company declares increased cash dividend of $0.03 per share